Chardan lowered the firm’s price target on Intellia Therapeutics (NTLA) to $88 from $94 and keeps a Buy rating on the shares after ...

Director Jang Hang-joon's new film "The Man Who Lives With The King" (Gaje) confirmed the main cast and unveiled a prominent ...

This image, provided by Showbox, shows the main cast for filmmaker Jang Hang-jun's upcoming historical film, tentatively ...

Here are the top five Korean dramas showcasing Park Shin Hye's stellar performances, ranging from 'The Judge From Hell' to ...

South Korea’s Ryu Hae-ran isn’t complaining about being second after the first round of the Maybank Championship yesterday.

Thursday was hardly a good day to be a shareholder of Intellia Therapeutics ( NTLA -20.51%). After the biotech delivered some news from the lab and witnessed one analyst's negative reaction to it, the ...

If a phone or other electronic device was made of soft materials, how would that change its use? Would it be more durable? If hospital health monitoring equipment was made of less rigid components, ...

Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...

Greta Lee, best known for her role in Past Lives, will replace Sandra Hüller in the cast of Late Fame and star alongside ...

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.

A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...

Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...